Dexcom jumps after study shows Type 2 diabetics benefit from CGM products
DexCom announced, last night, the publication of a new study that shows people with Type 2 diabetes on a multiple daily injection, MDI, insulin therapy benefit from the use of continuous glucose monitoring, CGM. Participants in the study achieved significant A1C reduction and spent more time in range, regardless of age, education or math ability. The findings are the result of the DIaMonD study- -Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes, which assessed the impact of CGM on glycemic control in individuals with Type 2 diabetes on MDI insulin therapy. Results from a parallel arm of the study using participants with Type 1 diabetes were published in January 2017. "This study represents a significant step forward for the diabetes community," said Roy Beck, MD, lead study investigator from the Jaeb Center for Health Research. "The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions." Shares of Dexcom are up over 4% to $76.18 in morning trading.